一表汇总,阿托品的各种应用 !

2016-03-22 医学之声 医学之声

阿托品为阻断M胆碱受体的抗胆碱药,能解除平滑肌的痉挛(包括解除血管痉挛,改善微血管循环);抑制腺体分泌;解除迷走神经对心脏的抑制,使心跳加快;散大瞳孔,使眼压升高;兴奋呼吸中枢。总结如下表:

阿托品为阻断M胆碱受体的抗胆碱药,能解除平滑肌的痉挛(包括解除血管痉挛,改善微血管循环);抑制腺体分泌;解除迷走神经对心脏的抑制,使心跳加快;散大瞳孔,使眼压升高;兴奋呼吸中枢。总结如下表:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1645832, encodeId=afca1645832fa, content=<a href='/topic/show?id=418a9e82332' target=_blank style='color:#2F92EE;'>#阿托品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97823, encryptionId=418a9e82332, topicName=阿托品)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fd723235219, createdName=陈吴1242, createdTime=Sun Feb 26 19:52:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75371, encodeId=7f4de537162, content=一目了然, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0ee1691188, createdName=1de5ae28m43(暂无匿称), createdTime=Sun Apr 03 13:25:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72810, encodeId=6005e2810a8, content=很好的总结, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Mar 23 06:44:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72746, encodeId=818ce274669, content=比较好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44b91679772, createdName=1de304d2m86(暂无匿称), createdTime=Tue Mar 22 20:17:00 CST 2016, time=2016-03-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1645832, encodeId=afca1645832fa, content=<a href='/topic/show?id=418a9e82332' target=_blank style='color:#2F92EE;'>#阿托品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97823, encryptionId=418a9e82332, topicName=阿托品)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fd723235219, createdName=陈吴1242, createdTime=Sun Feb 26 19:52:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75371, encodeId=7f4de537162, content=一目了然, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0ee1691188, createdName=1de5ae28m43(暂无匿称), createdTime=Sun Apr 03 13:25:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72810, encodeId=6005e2810a8, content=很好的总结, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Mar 23 06:44:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72746, encodeId=818ce274669, content=比较好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44b91679772, createdName=1de304d2m86(暂无匿称), createdTime=Tue Mar 22 20:17:00 CST 2016, time=2016-03-22, status=1, ipAttribution=)]
    2016-04-03 1de5ae28m43(暂无匿称)

    一目了然

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1645832, encodeId=afca1645832fa, content=<a href='/topic/show?id=418a9e82332' target=_blank style='color:#2F92EE;'>#阿托品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97823, encryptionId=418a9e82332, topicName=阿托品)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fd723235219, createdName=陈吴1242, createdTime=Sun Feb 26 19:52:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75371, encodeId=7f4de537162, content=一目了然, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0ee1691188, createdName=1de5ae28m43(暂无匿称), createdTime=Sun Apr 03 13:25:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72810, encodeId=6005e2810a8, content=很好的总结, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Mar 23 06:44:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72746, encodeId=818ce274669, content=比较好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44b91679772, createdName=1de304d2m86(暂无匿称), createdTime=Tue Mar 22 20:17:00 CST 2016, time=2016-03-22, status=1, ipAttribution=)]
    2016-03-23 milkshark

    很好的总结

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1645832, encodeId=afca1645832fa, content=<a href='/topic/show?id=418a9e82332' target=_blank style='color:#2F92EE;'>#阿托品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97823, encryptionId=418a9e82332, topicName=阿托品)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fd723235219, createdName=陈吴1242, createdTime=Sun Feb 26 19:52:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75371, encodeId=7f4de537162, content=一目了然, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0ee1691188, createdName=1de5ae28m43(暂无匿称), createdTime=Sun Apr 03 13:25:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72810, encodeId=6005e2810a8, content=很好的总结, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Mar 23 06:44:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72746, encodeId=818ce274669, content=比较好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44b91679772, createdName=1de304d2m86(暂无匿称), createdTime=Tue Mar 22 20:17:00 CST 2016, time=2016-03-22, status=1, ipAttribution=)]
    2016-03-22 1de304d2m86(暂无匿称)

    比较好!

    0

相关资讯

中国药学会发布高警示药品目录

5月27日,中国药学会医院药学专业委员用药安全专家组在京召开用药错误案例解析研讨会,并在会上发布包含24个大类和14个品种药物的《高警示药品目录》。 记者注意到,高警示药品并不高端,《目录》中不乏胰岛素、抗血栓药、抗心律失常药等常见药物,甚至包括氯化钠注射液、100毫升以上大容量灭菌注射用水。 中国药学会医院药学专业委员用药安全专家组组长张晓乐介绍,高警示药品此前惯称“高危药品”,是指